UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 89

Sortiert nach

Abstract OT1-01-08: Intensified alkylating chemotherapy in patients with oligo-metastatic breast cancer harboring homologous recombination deficiency: The OLIGO study

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT1-01-08-OT1-01-08

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT1-03-10: A phase I followed by a r andomiz e d phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy v ersus capec i tabine in BRCA-1 or -2 mutated Her2 negative ad v anced breast c a ncer as first l ine treatment (REVIVAL study)

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.OT1-03-10-OT1-03-10

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT1-1-01: Optimizing neoadjuvant systemic treatment in HER2 positive breast cancer - The TRAIN-2 study

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.OT1-1-01-OT1-1-01

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT2-01-11-OT2-01-11

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT2-07-08: Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trial

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.OT2-07-08-OT2-07-08

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT2-1-02: Clinical node negative breast cancer patients undergoing breast conserving therapy: follow-up versus sentinel lymph node biopsy

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.OT2-1-02-OT2-1-02

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT2-1-03: The Z11 design for breast cancer patients undergoing a mastectomy

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.OT2-1-03-OT2-1-03

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-06-07: Characterization of chromosomal instability in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P1-P1-06-07

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-13-10: Adjuvant treatment of HER2+ breast cancer: Should trastuzumab be given sequentially or concurrently with chemotherapy?

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-13-10

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-14-16: Weekly paclitaxel, trastuzumab, carboplatin is a highly effective neoadjuvant regimen in HER2-positive breast cancer: Results from the TRAIN-study

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P1-P1-14-16

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-15-05: GSTP1 polymorphism is associated with chemotherapy induced neuropathy

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P1-P1-15-05

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-09-16: How population-based data complement trial data in the adjuvant endocrine treatment of ER+/HER2+ breast cancers

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P2-P2-09-16

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-07-28: BRCA1-like profile as predictive biomarker in non myeloablative chemotherapy (GAIN study)

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P3-P3-07-28

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-08-06: Phosphorylation of insulin-like growth factor-1 receptor (IGF-1R) is associated with tamoxifen resistance by activating the PI3K/MAPK pathway

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P4-P4-08-06

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-14-11: No impact of osteoporosis or bisphosphonate use for osteoporosis on breast cancer outcome: A sub-study of the DATA trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-14-11

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-21-30: Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-21-30

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-08-07: The long-term prognosis of breast cancers patients diagnosed ≤40 years in the absence of adjuvant systemic therapy

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P5-P5-08-07

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-14-03: Adjuvant dose dense doxorubicin-cyclophosphamide (ddAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P5-P5-14-03

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-06-13: Optimized prediction of clinical outcome by the PREDICT plus tool and the 70-gene signature in early stage node-negative breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P6-P6-06-13

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-07-05: Prognosis of 368 women with primary breast cancer during pregnancy: results from an international collaborative trial

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P6-P6-07-05

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-08-06: Neoadjuvant tamoxifen therapy synchronizes ERα binding and gene expression profiles

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P6-P6-08-06

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD01-02: Increased expression of phosporylated mTOR in metastatic breast tumors compared to primary tumors in patients who received adjuvant endocrine therapy

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.PD01-02-PD01-02

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD01-03: Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.PD01-03-PD01-03

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD01-04: Histological Features of ER-Low, HER2-Negative Breast Cancer Predict Response to High Dose, Platinum-Based Chemotherapy

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.PD01-04-PD01-04

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD4-12: Clustering of activated proteins of the PI3K and MAPK pathways distinguishes ER+/HER2- primary breast cancer patients with preferential tamoxifen benefit

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD4-12-PD4-12

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 89

Suche als RSS-Feed

Aktive Filter

Nur zeigenMit Volltextzugriff

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Publikationsform

Artikel
(89)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(38)
Life Sciences & Biomedicine
(37)
Humans
(27)
Biological And Medical Sciences
(19)
Female
(17)
Adult
(15)
Business & Economics
(15)
Social Sciences
(15)
Oncology
(14)
Economics
(13)
Business, Finance
(12)
Medical Sciences
(12)
Breast Cancer
(10)
Middle Aged
(10)
Studies
(9)
Fundamental And Applied Biological Sciences. Psychology
(7)
Male
(7)
Northern America
(7)
U.S
(7)
Animals
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Abstract OT1-01-08: Intensified alkylating chemotherapy in patients with oligo-metastatic breast cancer harboring homologous recombination deficiency: The OLIGO study

Abstract OT1-03-10: A phase I followed by a r andomiz e d phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy v ersus capec i tabine in BRCA-1 or -2 mutated Her2 negative ad v anced breast c a ncer as first l ine treatment (REVIVAL study)

Abstract OT1-1-01: Optimizing neoadjuvant systemic treatment in HER2 positive breast cancer - The TRAIN-2 study

Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Abstract OT2-07-08: Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trial

Abstract OT2-1-02: Clinical node negative breast cancer patients undergoing breast conserving therapy: follow-up versus sentinel lymph node biopsy

Abstract OT2-1-03: The Z11 design for breast cancer patients undergoing a mastectomy

Abstract P1-06-07: Characterization of chromosomal instability in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

Abstract P1-13-10: Adjuvant treatment of HER2+ breast cancer: Should trastuzumab be given sequentially or concurrently with chemotherapy?

Abstract P1-14-16: Weekly paclitaxel, trastuzumab, carboplatin is a highly effective neoadjuvant regimen in HER2-positive breast cancer: Results from the TRAIN-study

Abstract P1-15-05: GSTP1 polymorphism is associated with chemotherapy induced neuropathy

Abstract P2-09-16: How population-based data complement trial data in the adjuvant endocrine treatment of ER+/HER2+ breast cancers

Abstract P3-07-28: BRCA1-like profile as predictive biomarker in non myeloablative chemotherapy (GAIN study)

Abstract P4-08-06: Phosphorylation of insulin-like growth factor-1 receptor (IGF-1R) is associated with tamoxifen resistance by activating the PI3K/MAPK pathway

Abstract P4-14-11: No impact of osteoporosis or bisphosphonate use for osteoporosis on breast cancer outcome: A sub-study of the DATA trial

Abstract P4-21-30: Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle

Abstract P5-08-07: The long-term prognosis of breast cancers patients diagnosed ≤40 years in the absence of adjuvant systemic therapy

Abstract P5-14-03: Adjuvant dose dense doxorubicin-cyclophosphamide (ddAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04)

Abstract P6-06-13: Optimized prediction of clinical outcome by the PREDICT plus tool and the 70-gene signature in early stage node-negative breast cancer

Abstract P6-07-05: Prognosis of 368 women with primary breast cancer during pregnancy: results from an international collaborative trial

Abstract P6-08-06: Neoadjuvant tamoxifen therapy synchronizes ERα binding and gene expression profiles

Abstract PD01-02: Increased expression of phosporylated mTOR in metastatic breast tumors compared to primary tumors in patients who received adjuvant endocrine therapy

Abstract PD01-03: Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment

Abstract PD01-04: Histological Features of ER-Low, HER2-Negative Breast Cancer Predict Response to High Dose, Platinum-Based Chemotherapy

Abstract PD4-12: Clustering of activated proteins of the PI3K and MAPK pathways distinguishes ER+/HER2- primary breast cancer patients with preferential tamoxifen benefit

Aktive Filter

Suchergebnisse filtern